Novel Hyaluronan Formulation Enhances the Efficacy of Boron Neutron Capture Therapy for Murine Mesothelioma
Overview
Affiliations
Background: Malignant pleural mesothelioma (MPM) is a refractory cancer of the pleura caused by asbestos exposure. MPM is difficult to treat because it easily disseminates. Boron neutron capture therapy (BNCT) is a radiotherapy in which cancer cells that selectively take up (10)Boron-containing compounds are destroyed, and normal cells are uninjured. Hyaluronan (HA) is a ligand of cluster of differentiation 44 (CD44), that is expressed on MPM cells.
Materials And Methods: In order to enhance BNCT for MPM tumors, we developed a novel HA-containing (10)B (sodium borocaptate: BSH) formulation (HA-BND-S). We examined the efficacy of HA-BND-S using MPM cells and a mouse MPM model.
Results: HA-BND-S preferentially bound MPM cells dose-dependently, and increased the cytotoxicity of BNCT compared to BSH in vitro. HA-BND-S administration significantly increased the survival of MPM tumor-bearing mice compared to BSH at the same (10)B dosage in BNCT.
Conclusion: Modifying BSH with HA is a promising strategy for enhancing the efficacy of BNCT for therapy of MPM.
Sforzi J, Lanfranco A, Stefania R, Alberti D, Bitonto V, Parisotto S Sci Rep. 2023; 13(1):620.
PMID: 36635364 PMC: 9837127. DOI: 10.1038/s41598-023-27625-0.
Towards Enhanced MRI Performance of Tumor-Specific Dimeric Phenylboronic Contrast Agents.
Martinelli J, Tei L, Crich S, Alberti D, Djanashvili K Molecules. 2021; 26(6).
PMID: 33808910 PMC: 8003780. DOI: 10.3390/molecules26061730.
Alberti D, Michelotti A, Lanfranco A, Protti N, Altieri S, Deagostino A Sci Rep. 2020; 10(1):19274.
PMID: 33159147 PMC: 7648750. DOI: 10.1038/s41598-020-76370-1.
Inflammatory Alteration of Human T Cells Exposed Continuously to Asbestos.
Kumagai-Takei N, Yamamoto S, Lee S, Maeda M, Masuzzaki H, Sada N Int J Mol Sci. 2018; 19(2).
PMID: 29419731 PMC: 5855726. DOI: 10.3390/ijms19020504.